Following FDA approval, LabCorp has now introduced an at-home test for the COVID-19 virus. It will initially be made available to health care workers and first responders in 46, but not all 50 states — the missing states being New York, New Jersey, Rhode Island, and Maryland. The reason, according to an Associated Press report, is that several states have laws on the books that restrict testing with at-home collection kits. I examine the frustrating situation in a new Cato post.
After I published the piece, I was contacted by Paul Celli, public health administrator for clinical and forensic laboratories at the Maryland Department of Health Office of Health Care Quality, who wrote to say the AP article is incorrect in listing Maryland as a state that bans at-home testing. Whatever may be the situation in the other three states, “Maryland is not banning this Pixel at‐home collection device (it is not a test) for use at select Labcorp testing locations.” A Maryland legislative source points out that last year, state lawmakers approved and Gov. Hogan signed SB 495, a measure aimed at liberalizing access to medical testing by removing some of the restrictions in effect earlier. Mr. Celli writes that even before that change, rather than bar use of this particular test the state “probably would have exercised enforcement discretion in such cases where the company appears to be providing services pursuant to a physician or other authorized provider order for the test.”